The Scottish Medicines Consortium (SMC) has just approved Apalutamide (brand name Erleada®) for use by NHS Scotland. The drug is used for treatment in men with metastatic hormone-sensitive prostate cancer (mHSPC), in combination with androgen deprivation therapy (ADT).
The drug has the potential to make a real difference for men whose cancer has spread but remains sensitive to hormone treatment.
The decision was welcomed by our colleagues at Prostate Scotland, who have written the following informative press release:
Prostate Scotland Press Release
Further details from the SMC can be found here: Public Summary – Decision Explained